Volume 19 Issue 10
Oct.  2021
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2021  >  19(10): 1729-1732
GUAN Jing-jing, CHEN Yu, TANG Hua-dong, ZHOU Ping-hui. Current status and challenges of health management for osteoporosis[J]. Chinese Journal of General Practice, 2021, 19(10): 1729-1732. doi: 10.16766/j.cnki.issn.1674-4152.002153
Citation: GUAN Jing-jing, CHEN Yu, TANG Hua-dong, ZHOU Ping-hui. Current status and challenges of health management for osteoporosis[J]. Chinese Journal of General Practice, 2021, 19(10): 1729-1732. doi: 10.16766/j.cnki.issn.1674-4152.002153
shu

Current status and challenges of health management for osteoporosis

doi: 10.16766/j.cnki.issn.1674-4152.002153
  • 1.

    Health Management Centre, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China

Funds:

 31700854

 KJ2018A1011

  • Received Date: 2020-12-11
    Available Online: 2022-02-15
    Abstract
  • Osteoporosis is the main cause of osteoporosis fracture in the elderly, which seriously affects the quality of life of patients and increases economic burden. The main causes of osteoporosis include the decrease of bone density, the destruction of bone microstructure and the decrease of bone strength. At present, the main treatment for decreased bone mineral density is to use anti-bone absorption drugs (such as bisphosphonates, calcitonin), bone formation-promoting drugs (parathyroid hormone) and some traditional Chinese medicine. However, the effect of drug treatment is not ideal. Despite surgical intervention, many complications exist. In recent years, with the establishment of the idea of three-level prevention, the health management of osteoporosis from the perspective of one-level prevention has become the mainstream method to prevent osteoporosis and related fractures. In this study, the source of osteoporosis health management and the relationship between patients and medical staff are introduced briefly, including some measures of osteoporosis health management and the challenges in the current development. In addition, the osteoporosis of postmenopausal women is mainly caused by the decrease of bone density caused by the loss of oestrogen. Thus, its preventive measures are different from those of senile osteoporosis, which should be described separately. The current situation of the three-level diagnosis and treatment system in China needs to be solved, a more scientific evaluation standard of osteoporosis should be developed, and patients' compliance with diet and living habits in the health management plan need to be strengthened. In addition, we should improve and develop the application of oestrogen in the health management of perimenopausal women's osteoporosis from the type, dose, duration and individual situation of estrogen, and finally play the primary preventive role of health management in osteoporosis and related fractures.

     

    • FullText(HTML)
  • loading
    • References(41)
  • [1]
    LESLIE W D, MORIN S N. Osteoporosis epidemiology 2013: Implications for diagnosis, risk assessment, and treatment[J]. Curr Opin Rheumatol, 2014, 26(4): 440-446. doi: 10.1097/BOR.0000000000000064
    [2]
    CHEN P, LI Z, HU Y. Prevalence of osteoporosis in China: A meta-analysis and systematic review[J]. BMC Public Health, 2016, 16(1): 1039. doi: 10.1186/s12889-016-3712-7
    [3]
    罗令, 孙晓峰, 皮丕喆, 等. 近10年来我国中老年人群骨质疏松症患病率的荟萃分析[J]. 中国骨质疏松杂志, 2018, 24(11): 1415-1420. doi: 10.3969/j.issn.1006-7108.2018.11.005
    [4]
    KHOSLA S, HOFBAUER L C. Osteoporosis treatment: Recent developments and ongoing challenges[J]. Lancet Diabetes Endocrinol, 2017, 5(11): 898-907. doi: 10.1016/S2213-8587(17)30188-2
    [5]
    ZHANG N D, HAN T, HUANG B K, et al. Traditional Chinese medicine formulas for the treatment of osteoporosis: Implication for antiosteoporotic drug discovery[J]. J Ethnopharmacol, 2016, 189: 61-80. doi: 10.1016/j.jep.2016.05.025
    [6]
    RUSSELL L A. Osteoporosis and orthopedic surgery: Effect of bone health on total joint arthroplasty outcome[J]. Curr Rheumatol Rep, 2013, 15(11): 371. doi: 10.1007/s11926-013-0371-x
    [7]
    温勇. 健康管理对中老年骨质疏松症患者生活质量影响的Meta分析[D]. 广州: 广州中医药大学, 2016.
    [8]
    潘小红. 老年骨质疏松患者饮食行为干预及健康管理研究[J]. 名医, 2018(9): 40. https://www.cnki.com.cn/Article/CJFDTOTAL-MGYI201809032.htm
    [9]
    白颖, 杨明珠, 杨雪, 等. 骨质疏松骨折患者的健康管理及效果分析[J]. 中国骨质疏松杂志, 2014, 20(12): 1450-1452. doi: 10.3969/j.issn.1006-7108.2014.12.017
    [10]
    CHANG H C, HSIEH C F, LIN Y C, et al. Does coffee drinking have beneficial effects on bone health of Taiwanese adults? A longitudinal study[J]. BMC Public Health, 2018, 18(1): 1273. doi: 10.1186/s12889-018-6168-0
    [11]
    毕娜, 丁红, 苏天娇, 等. 社区骨质疏松患者饮食行为及健康管理策略[J]. 中国骨质疏松杂志, 2017, 23(4): 452-455. doi: 10.3969/j.issn.1006-7108.2017.04.007
    [12]
    许倩, 宋志雪, 陈长香, 等. 早骨质疏松老年人自我健康管理行为状况分析[J]. 中国骨质疏松杂志, 2016, 22(8): 1012-1015. doi: 10.3969/j.issn.1006-7108.2016.08.015
    [13]
    EXPERT PANEL ON MUSCULOSKELETAL IMAGING, WARD R J, ROBERTS C C, et al. ACR Appropriateness Criteria? Osteoporosis and bone mineral density[J]. J Am Coll Radiol, 2017, 14(5S): S189-S202. http://f.i-md.com/medinfo/material/012/4eb0148f44aee4f554e17012/4eb014ad44aee4f554e17015.pdf
    [14]
    张智海, 刘忠厚, 李娜, 等. 中国人骨质疏松症诊断标准专家共识(第三稿·2014版)[J]. 中国骨质疏松杂志, 2014, 20(9): 1007-1010. doi: 10.3969/j.issn.1006-7108.2014.09.001
    [15]
    SALE J E, HAWKER G, CAMERON C, et al. Perceived messages about bone health after a fracture are not consistent across healthcare providers[J]. Rheumatol Int, 2015, 35(1): 97-103. doi: 10.1007/s00296-014-3079-y
    [16]
    李夏珀, 覃素娇, 谈佳, 等. 基于唤醒教育的健康管理对骨质疏松患者健康信念、行为及骨密度的影响[J]. 广西医学, 2018, 40(15): 1761-1764. https://www.cnki.com.cn/Article/CJFDTOTAL-GYYX201815045.htm
    [17]
    SCOTT T A, BEVERIDGE A, NI CHRONIN D. Suboptimal bone protection in geriatric inpatients and effect of a simple educational and mnemonic strategy[J]. Australas J Ageing, 2016, 35(3): E36-E39. doi: 10.1111/ajag.12320
    [18]
    GOODE J V, SWIGER K, BLUML B M. Regional osteoporosis screening, referral, and monitoring program in community pharmacies: Findings from Project ImPACT: Osteoporosis[J]. J Am Pharm Assoc, 2004, 44(2): 152-160. doi: 10.1331/154434504773062609
    [19]
    NIK J, LAI P S, NG C J, et al. A qualitative study of community pharmacists' opinions on the provision of osteoporosis disease state management services in Malaysia[J]. BMC Health Serv Res, 2016, 16(1): 448. doi: 10.1186/s12913-016-1686-x
    [20]
    ZHANG J, LIU X, LI H, et al. Exosomes/tricalcium phosphate combination scaffolds can enhance bone regeneration by activating the PI3K/qkt signaling pathway[J]. Stem Cell Res Ther, 2016, 7(1): 136. doi: 10.1186/s13287-016-0391-3
    [21]
    LIANG J, CHEN C, LIU H, et al. Gossypol promotes bone formation in ovariectomy-induced osteoporosis through regulating cell apoptosis[J]. Biomed Res Int, 2018: 3635485. http://downloads.hindawi.com/journals/bmri/2018/3635485.pdf
    [22]
    LI T, JIANG S, LU C, et al. Melatonin: Another avenue for treating osteoporosis?[J]. J Pineal Res, 2019, 66(2): e12548. doi: 10.1111/jpi.12548
    [23]
    BLACK D M. Postmenopausal osteoporosis[J]. N Engl J Med, 2016, 374(21): 2096-2097.
    [24]
    崔燎. 骨质疏松症的药物防治: 难点与展望[J]. 广东医科大学学报, 2020, 38(2): 127-133. doi: 10.3969/j.issn.1005-4057.2020.02.001
    [25]
    FINKELSTEIN J S, WYLAND J J, LEE H. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis[J]. J Clin Endocrinol Metab, 2010, 95(4): 1838-1845. doi: 10.1210/jc.2009-1703
    [26]
    SAAG K G, SHANE E, BOONEN S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis[J]. N Engl J Med, 2007, 357(20): 2028-2039. doi: 10.1056/NEJMoa071408
    [27]
    COMPSTON J, COOPER A, COOPER C, et al. UK clinical guideline for the prevention and treatment of osteoporosis[J]. Arch Osteoporos, 2017, 12(1): 43. doi: 10.1007/s11657-017-0324-5
    [28]
    LEDER B Z, NEER R M, WYLAND J J, et al. Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis[J]. J Clin Endocrinol Metab, 2009, 94(8): 2915-2921. doi: 10.1210/jc.2008-2630
    [29]
    LORENTZON M. Treating osteoporosis to prevent fractures: current concepts and future developments[J]. J Intern Med, 2019, 285(4): 381-394. doi: 10.1111/joim.12873
    [30]
    刘清阁, 马晓勇, 郭志学, 等. 金乌骨通对预防绝经女性骨质疏松性骨折的疗效研究[J]. 中国医药导刊, 2014, 16(12): 1501-1504. doi: 10.3969/j.issn.1009-0959.2014.12.028
    [31]
    梁玲玲, 李璐兵, 刘涛. 阿仑膦酸钠预防妇女绝经后脆性骨折效果的Meta分析[J]. 新疆医科大学学报, 2016, 39(4): 460-463. doi: 10.3969/j.issn.1009-5551.2016.04.019
    [32]
    宋永进, 应锦河. 阿托伐他汀联合雌激素在绝经期骨质疏松女性患者中的应用价值[J]. 中华全科医学, 2016, 14(9): 1485-1487. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201609019.htm
    [33]
    谢炎秋, 蒋本泰. 唑来膦酸与替勃龙治疗绝经后骨质疏松疗效比较及对骨折的预防作用[J]. 实用药物与临床, 2014, 17(7): 918-920. https://www.cnki.com.cn/Article/CJFDTOTAL-LYLC201407031.htm
    [34]
    LEVIN V A, JIANG X, KAGAN R. Estrogen therapy for osteoporosis in the modern era[J]. Osteoporos Int, 2018, 29(5): 1049-1055. doi: 10.1007/s00198-018-4414-z
    [35]
    GAMBACCIANI M, LEVANCINI M. Hormone replacement therapy and the prevention of postmenopausal osteoporosis[J]. Prz Menopauzalny, 2014, 13(4): 213-220. http://search.ebscohost.com/login.aspx?direct=true&db=aph&AN=98177781&site=ehost-live
    [36]
    KOMM B S, MORGENSTERN D, A YAMAMOTO L, et al. The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women[J]. Expert Rev Clin Pharmacol, 2015, 8(6): 769-784. doi: 10.1586/17512433.2015.1099432
    [37]
    MANSON J E, CHLEBOWSKI R T, STEFANICK M L, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials[J]. JAMA, 2013, 310(13): 1353-1368. doi: 10.1001/jama.2013.278040
    [38]
    CHLEBOWSKI R T, ANDERSON G L, GASS M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women[J]. JAMA, 2010, 304(15): 1684-1692. doi: 10.1001/jama.2010.1500
    [39]
    TREMOLLIERES F. Assessment and hormonal management of osteoporosis[J]. Climacteric, 2019, 22(2): 122-126. doi: 10.1080/13697137.2018.1555582
    [40]
    PASSOS-SOARES J S, VIANNA M I P, GOMES-FILHO I S, et al. Association between osteoporosis treatment and severe periodontitis in postmenopausal women[J]. Menopause, 2017, 24(7): 789-795. doi: 10.1097/GME.0000000000000830
    [41]
    DODD D Z, ROWE D J. The relationship between postmenopausal osteoporosis and periodontal disease[J]. J Dent Hyg, 2013, 87(6): 336-344. http://jdh.adha.org/content/87/6/336.full.pdf
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (755) PDF downloads(40) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return